The incidence and risk factors of pulmonary infection complications in lung cancer patients treated with immune checkpoint inhibitors Authors: Haixia Yang, Yaxuan Han, Xiaosha Zhou, Jianying Li, Yanjun Zhao, Shanshan Zhang Published: 2025 ABSTRACT AbstractBackground Immune checkpoint inhibitor-related pneumonitis in patients with lung cancer has been well managed. However, pulmonary infections following the use of immune checkpoint inhibitors (ICIs) have not been fully studied. This study aimed to investigate the incidence, pathogen distribution, and risk factors of pulmonary infections in lung cancer patients receiving ICIs therapy.Methods A retrospective analysis was conducted on 107 lung cancer patients treated with PD-1/PD-L1 inhibitors at a single institution. Pulmonary infections were defined as grade ≥2 (CTCAE v5.0) and confirmed microbiologically or clinically. Data on demographics, comorbidities, treatment details, and outcomes were analyzed. Cumulative incidence of grade 2-5 pulmonary infections following ICIs therapy was assessed using Kaplan-Meier methodology. Univariate and multivariate logistic regression identified risk factors.Results Among the 107 patients, 44 (41.1%, 44/107) developed pulmonary infections during a median follow-up of 8 months.Of these, 25 (56.8%, 25/44) cases of pulmonary infection were confirmed by etiological examination, and 19 were diagnosed clinically. The 25 infected patients had a total of 58 infections (primary causative microorganisms), among which the frequencies of bacterial, fungal, viral, and mycobacterial infections were 24 (41.4%, 24/58), 21 (36.2%, 21/58), 9 (15.5%, 9/58), and 4 (6.9%, 4/58), respectively. Notably, in the confirmed cases, 76.0%(19/25) exhibited mixed infections.Among 18 lung cancer patients with concurrent pulmonary tuberculosis(PTB), 11 developed pulmonary infections (61.1%,11/18), and 5 of these experienced progression or new-onset PTB. The incidence of pulmonary infection among those receiving thoracic radiotherapy (TRT) was 58.3% (21/36), and the V20 value in the infection group was significantly higher than in the non-infection group (p= 0.0395). Independent risk factors for pulmonary infection included age ≥65 years (adjusted OR = 3.705, p=0.007), lmaging-Suggested Interstitial Pulmonary Abnormality (ISIPA) (adjusted OR = 7.459, p= 0.001), TRT (adjusted OR = 5.141, p= 0.002), and a history of tuberculosis (adjusted OR = 4.676, p= 0.015).Conclusions Among lung cancer patients receiving immune checkpoint inhibitors (ICIs), there is a notably high incidence of pulmonary infections. The prevalence of mixed infections suggests the need for multiple coverage of pathogenic microorganisms. Independent risk factors included age ≥65, pre-existing ISIPA, thoracic radiotherapy, and prior PTB. The association between ICI therapy and radiotherapy warrants further investigation. Additional prospective studies are required to confirm these findings and guide optimal clinical management strategies.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-025-15105-9.Keywords: Immune checkpoint inhibitors, Pulmonary infection, Lung cancer, Risk factors, Thoracic radiotherapy, Tuberculosis Background Immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-PD-L1 agents, have transformed cancer treatment by facilitating enhanced immune recognition, inducing targeted apoptosis, and promoting more effective immune-mediated tumor clearance, thereby overcoming tumor immune evasion [1]. As cornerstone therapies in oncology, ICIs now constitute essential components of comprehensive treatment regimens for lung cancer across various disease stages [2, 3]. However, the systemic immune activation triggered by ICIs often leads to immune-related adverse events (irAEs) that affect multiple organ systems. Immune checkpoint inhibitor-associated pneumonitis (CIP) can have severe and potentially life-threatening consequences in non-small cell lung cancer (NSCLC) patients, with clinical manifestations further complicated by overlapping respiratory symptoms caused by both the tumor and immunotherapy [4]. This risk is markedly elevated when thoracic radiotherapy is administered concurrently, frequently requiring immunosuppressive interventions such as corticosteroids or tumor necrosis factor-α inhibitors, which may increase the susceptibility of patients to opportunistic infections [5, 6]. However, emerging evidence highlights infection risks in ICI-treated patients that are independent of immunosuppressive therapy. One study reported infections occurring in the absence of glucocorticoid or immunosuppressant use, hypothesing that ICI-induced T-lymphocyte trafficking to tumor sites may deplete circulating anti-infective T cells, thus increasing susceptibility to infections [7]. Nonetheless, the precise pathogenic mechanisms underlying this phenomenon remain unclear [8]. Additionally, several case reports suggest that immune ICIsmay increase susceptibility to Mycobacterium tuberculosis infection, potentially through mechanisms involving immune dysregulation [9]. The epidemiology of post-ICI infectious complications has recently garnered significant research attention. A retrospective analysis of 740 melanoma patients receiving ICIs revealed severe infections in 7.3% (54/740) of cases, with corticosteroid and/or infliximab use identified as primary risk factors [10]. French investigators reported that 18% (36/200) of ICI-treated patients developed infections (median onset: 47 days), with pulmonary infections constituting 58.3% of cases. No infection-related fatalities or opportunistic infections were observed [11]. Kohei Fujita et al. found that 19.2% (32/167) of NSCLC patients developed infectious complications during ICIs therapy, with bacterial pathogens predominating, followed by fungal and viral agents. Diabetes mellitus emerged as a significant risk factor (OR = 3.61) [12]. Davide Fiore Bavaro et al.’s retrospective analysis of 118 NSCLC patients receiving nivolumab or pembrolizumab demonstrated infection rates of 22–27%, primarily affecting pulmonary, dermatologic, urinary, and gastrointestinal systems. Importantly, mortality rates escalated proportionally with infection frequency, increasing from 10.7% to 40% [13]. These collective findings establish that post-ICI infections represent a clinically significant phenomenon with implications for patient survival, mandating heightened clinical vigilance. However, current evidence derives predominantly from retrospective analyses and case reports encompassing heterogeneous tumor types and infection sites. Consequently, the incidence and risk factors of pulmonary infections specifically following ICIs treatment in lung cancer patients remain insufficiently characterized. Critical knowledge gaps persist regarding infection epidemiology in comorbid populations (e.g.diabetes, Chronic Obstructive Pulmonary Disease(COPD), interstitial lung disease) and those receiving thoracic radiotherapy. In this context, the present study aims to systematically investigate pulmonary infection occurrence in ICI-treated lung cancer patients. Through comprehensive evaluation of infection incidence, pathogenic spectrum, and risk stratification for varying severity grades of infectious pneumonia, this research will establish an evidence base for optimizing preventive strategies and clinical management of post-ICI pulmonary infections. Methods Ethics approval and consent to participate This retrospective study was approved by the Institutional Review Board of Northwest University Affiliated Chest Hospital (Approval No. R2024-007-01) and was carried out in accordance with the ethical standards of the Declaration of Helsinki. Study population A total of 134 patients with pathologically confirmed malignant tumors in our hospital from May 2022 to January 2025, who received at least one cycle of PD-1/PD-L1 inhibitor treatment, were included. After excluding 27 patients with non-lung cancer tumors, secondary lung cancer, or incomplete clinical data, 107 patients were enrolled. Pulmonary infection occurrence was followed up from at least one month after ICIs treatment until the study end. Patients were divided into an infection group (n = 44) and a non-infection group (n = 63). The infection group included lung cancer patients diagnosed with pulmonary infection (microbiologically or clinically) and treated with anti-infective drugs, including those with CIP or radiation pneumonitis (RP) complicated by pulmonary infection. The non-infection group included patients without pulmonary infection or anti-infective drug use from ICIs treatment initiation to follow-up completion. Exclusion criteria were: (1) non-primary lung malignancies; (2) active pulmonary infection prior to ICIs initiation or infections resolved less than one month before treatment; (3) follow-up duration shorter than one month post-ICI therapy. Data collection Clinical data were extracted from electronic medical records including: Demographics: age, sex, body mass index (BMI) Demographics: age, sex, body mass index (BMI) Clinical characteristics: smoking history, Karnofsky Performance Status (KPS) score Clinical characteristics: smoking history, Karnofsky Performance Status (KPS) score Comorbidities: diabetes mellitus, hypertension Comorbidities: diabetes mellitus, hypertension Chronic lung diseases:Asthma was diagnosed based on medical records, while COPD, ISIPA and PTB were diagnosed using both medical records and imaging. According to the Chinese tuberculosis classification standard (WS 196-2017), PTB is categorized into three types: Fibrotic pulmonary tuberculosis(FPT), Active pulmonary tuberculosis(APT), and Latent tuberculosis infection(LTBI). FPT refers to stable lesions from past infections or treatments without active disease. APT indicates clinical evidence of Mycobacterium tuberculosis infection with active lesions. LTBI describes a condition where the body is infected with Mycobacterium tuberculosis but has no active lesions due to immune control [14]. For patients with APT, they must complete at least 3 weeks of standardized anti-tuberculosis treatment and show relief of clinical symptoms before starting ICIs treatment Chronic lung diseases:Asthma was diagnosed based on medical records, while COPD, ISIPA and PTB were diagnosed using both medical records and imaging. According to the Chinese tuberculosis classification standard (WS 196-2017), PTB is categorized into three types: Fibrotic pulmonary tuberculosis(FPT), Active pulmonary tuberculosis(APT), and Latent tuberculosis infection(LTBI). FPT refers to stable lesions from past infections or treatments without active disease. APT indicates clinical evidence of Mycobacterium tuberculosis infection with active lesions. LTBI describes a condition where the body is infected with Mycobacterium tuberculosis but has no active lesions due to immune control [14]. For patients with APT, they must complete at least 3 weeks of standardized anti-tuberculosis treatment and show relief of clinical symptoms before starting ICIs treatment Tumor characteristics: histologic type, TNM stage (AJCC 8th edition), PD-L1 expression level (tumor proportion score) Tumor characteristics: histologic type, TNM stage (AJCC 8th edition), PD-L1 expression level (tumor proportion score) Treatment details: number of ICIs cycles administered, thoracic radiotherapy parameters.GCS use :The use of Glucocorticoids (GCs) at a daily dose of ≥5 mg prednisone equivalent for a duration of 3 weeks or more(Supplementary Table 1-3) Treatment details: number of ICIs cycles administered, thoracic radiotherapy parameters.GCS use :The use of Glucocorticoids (GCs) at a daily dose of ≥5 mg prednisone equivalent for a duration of 3 weeks or more(Supplementary Table 1-3) Outcome measures Pulmonary infections were defined as either: Microbiologically confirmed: Identification was achieved through the analysis of bronchoalveolar lavage fluid (BALF) or sputum samples utilizing Next-generation sequencing(NGS)༈The interpretation of NGS results considers the number of detected pathogen sequences, their pathogenicity classification, clinical symptoms, and response to anti-infective treatment to identify the pathogen༉,Multiplex PCR for respiratory pathogens, conventional cultures, or smear microscopy Microbiologically confirmed: Identification was achieved through the analysis of bronchoalveolar lavage fluid (BALF) or sputum samples utilizing Next-generation sequencing(NGS)༈The interpretation of NGS results considers the number of detected pathogen sequences, their pathogenicity classification, clinical symptoms, and response to anti-infective treatment to identify the pathogen༉,Multiplex PCR for respiratory pathogens, conventional cultures, or smear microscopy Clinically diagnosed: Based on the presence of new radiographic infiltrates accompanied by clinically compatible symptoms, and a demonstrated response to empirical antibiotic therapy. Clinically diagnosed: Based on the presence of new radiographic infiltrates accompanied by clinically compatible symptoms, and a demonstrated response to empirical antibiotic therapy. All infections in this study must reach a severity of ≥ grade 2 as defined by the CTCAE version 5.0 [15]. For cases of CIP or RP complicated by pulmonary infection, both corticosteroids and antibacterial drugs are used for treatment simultaneously. Statistical analysis Continuous variables were presented as (normally distributed) or median with interquartile range (non-normal distribution). Categorical variables were expressed as frequencies (percentages). Time-to-event analysis was performed using Kaplan-Meier methodology to assess time from ICIs initiation to infection development. Univariate comparisons employed Fisher’s exact tests (categorical variables) and Student’s t-tests (continuous variables). Variables with p < 0.1 in univariate analysis were entered into multivariate logistic regression models to identify independent risk factors. All analyses were conducted using GraphPad Prism version 8.0 (GraphPad Software, San Diego, CA), with two-tailed p-values < 0.05 considered statistically significant. Results Incidence and pathogen distribution of pulmonary infections following ICIs therapy Among 107 enrolled lung cancer patients treated with ICIs, 44 patients (41.1%) developed grade ≥ 2 pulmonary infections during a median follow-up of 8 months (Q1, Q3:3–15 months). All infected patients received antimicrobial treatment, with 17 (38.6%,17/44) requiring additional corticosteroid therapy.Microbiological confirmation was obtained in 25 cases (25/44, 56.8%), while 19 (19/44, 43.2%) were clinically diagnosed. We have separately listed the 25 patients with clear pathogenic evidence, those with infection as primary causative microorganisms and those with potential contamination infection (Supplementary Table 4). Most patients (77.3%, 34 out of 44) encountered single infection episodes. In contrast, 13.6% (6 out of 44) and 9.1% (4 out of 44) of the patients had two and three infection episodes, respectively. The patients with two infections (n = 6) were predominantly infected by bacteria. Regarding the patients with three infections (n = 4), the first infection was mainly caused by bacteria, while the second and third infections were mainly a combination of bacteria with fungi or viruses. It is noteworthy that among the four patients who experienced three infections, three had infected COVID-19 (Supplementary Table 5). Among the 25 patients with microbiological diagnosis, a total of 74 infection episodes were recorded, including 58 major causative pathogens and 16 considered as potential contaminants.Among the 58 major pathogenic microorganisms, bacteria being the most frequently detected (n = 24), followed by fungi (n = 21), viruses (n = 9), and mycobacteria (n = 4). Among microbiologically confirmed cases, 24.0% (6/25) were monomicrobial and 76% (19/25) polymicrobial (Table 1).This study identified three cases of pulmonary infection combined with extrapulmonary infection (one each in the intestinal tract, skin, and urinary tract), and another three cases presented only with extrapulmonary infection (one each with gingival abscess, intestinal infection, and skin herpes). Table 1The primary causative pathogen distribution and pulmonary infection patterns in lung cancer patients receiving ICIsPathogens (species)FrequencyPathogens (species)FrequencyBacterial (11)24Fungal (5)21Klebsiella pneumoniae4Pneumocystis jirovecii7Streptococcus pneumoniae6Candida albicans5Stenotrophomonas maltophilia4Aspergillus spp.4Pseudomonas aeruginosa2Candida glabrata3Enterobacter cloacae2Candida tropicalis2Staphylococcus haemolyticus1Viral (3)9Haemophilus influenzae1COVID-195Enterococcus faecium1Influenza A virus3Methicillin-resistant S. aureus1Herpes simplex virus1Acinetobacter baumannii1Mycobacterial (1)4Corynebacterium striatum1Mycobacterium tuberculosis4Total frequency (Bacterial + Fungal + Viral + Mycobacterial) 58Total species (Bacterial + Fungal + Viral + Mycobacterial) 20Infection patternCasesMixed infection patternsCases(n = 19)Single-pathogen infection6 (24.0%)Bacterial + Fungal + Viral7 (28.0%)Bacterial + Fungal8 (32.0%)Bacterial + Bacterial3(12.0%)Fungal + Viral1 (4.0%) The primary causative pathogen distribution and pulmonary infection patterns in lung cancer patients receiving ICIs Cumulative incidence of grade 2–5 pulmonary infections following ICIs therapy in lung cancer patients Among 107 patients with lung cancer, the overall incidence of Grade 2–5 pulmonary infections was 41.1% (44/107). Specifically, the incidence rates for Grades 2, 3, 4, and 5 pulmonary infections were 3.7% (4/107), 31.8% (34/107), 3.7% (4/107), and 1.9% (2/107), respectively. The median time from the initiation of ICIs treatment to the onset of pulmonary infection was 4 months (Q1,Q3: 1–7 months). Notably, 68.2% (30/44) of the cases occurred within the first 6 months after ICIs treatment, while 18.2% (8/44) occurred more than 12 months post-treatment (all classified as Grade 2–3 pulmonary infections). According to CTCAE criteria, 6 patients (13.6%, 6/44) experienced Grade 4–5 pulmonary infections, all of which occurred within 7 months of treatment (Fig. 1). Among the 44 patients with pneumonia, 10 restartedICIs treatment following resolution of the infection, 28 permanently discontinued ICIs treatment, and the status of six patients remained unclear. Cumulative incidence of grade 2–5 pulmonary infections following ICIs therapy Analysis of tuberculosis status in lung cancer patients with pre-existing TB following ICIs therapy Among 107 lung cancer patients receiving ICIs treatment, 18 (18/107, 16.8%) had concomitant PTB, including 10 with FTB, 4 with APT and 4 with LTBI. Post-treatment evaluation revealed that 7 PTB patients remained infection-free, while 11 (61.1%, 11/18) developed pulmonary infections. Follow-up of PTB lesions in these 11 patients showed: among 6 FTB cases, 4 remained stable and 2 experienced recurrence (Fig. 2 A-B); 2 ATB cases showed no progression; and among 3 LTBI cases, 2 remained stable while 1 progressed to APT (Fig. 2 C-D). Notably, 2 patients without prior PTB history developed new-onset APT during ICIs treatment (Fig. 2E-F). In total, 5 cases demonstrated tuberculosis progression or new-onset APT, all confirmed through clinical symptoms, imaging, immunological testing (TST, T-Spot), and Mycobacterium tuberculosis molecular detection (TB-PCR, TB-DNA, TB-RNA, X-Pert MTB/RIF) in bronchoalveolar lavage fluid. The clinical characteristics of patients with active TB following ICI treatment are presented in supplementary Table 6. Representative CT images showing reactivation and progression of PTB in lung cancer patients after ICIs therapy. A-B Progression to APT (n=2); C-D Reactivation of LTBI (n=1); E-F New-onset APT post-ICIs therapy (n=2) Pulmonary infection incidence and dosimetric analysis in patients receiving combined ICIs and thoracic radiotherapy Among the 36 patients who received TRT, 21 (58.3%) developed pulmonary infections, and 15 (41.7%) remained infection-free. Of those with infections, 16 (16/21,76.2%) were diagnosed using etiological methods, and 5 (5/21,23.8%) were diagnosed based on clinical criteria. A total of 11 patients received anti-infective therapy alone, while 10 received combined therapy with anti-infectives and glucocorticoids (see Supplementary Table 2). Among the 10 patients, 8 were diagnosed via pathogen testing, and 2 were clinically diagnosed. The two clinically diagnosed cases might be CIP/RP or concurrent pulmonary infection. However, due to the administration of empirical “antibiotic + glucocorticoids " therapy, it was impossible to determine whether the observed clinical response was attributable to antibiotics, glucocorticoids, or their synergistic effect. Nevertheless, the high pathogen detection rate in this study supports the reliability of the reported pulmonary infection incidence. The median interval between the initiation of radiotherapy andICIs therapy was 4.5 months (Q1, Q3: 2–8 months). The mean target dose was 65 Gy (equivalent dose in 2 Gy fractions [EQD2]), with a median target volume of 230 cm³. Dosimetric parameters, including V5(Volume of tissue receiving at least 5 Gy of radiation dose), V10, V30, V40, and mean bilateral lungs dose, showed no significant differences between the infected and non-infected groups (p >0.05) (Table 2). In this study, all 36 patients receiving thoracic radiotherapy had bilateral lung dose-volume histogram (DVH) doses significantly below the thresholds recommended byNational Comprehensive Cancer Network (NCCN) guidelines for thoracic radiotherapy (V20 ≤ 28%, V5 ≤ 60%, meanlung dose(MLD) ≤ 20 Gy [16]. Despite this, 27.8%of patients (10/36) with pulmonary infections required additionalglucocorticoid treatment for radiation-induced or immune-relatedpneumonitis (Supplementary Table 2). Table 2Comparison of dosimetric parameters between infected and non-infected groups in 36 lung cancer patients undergoing radiotherapyDosimetric parameterInfection group (n = 21)Non-infection group (n = 15)t-valueP-valuebilateral lungs V5 (%)34.48 ± 11.3029.52 ± 12.591.0890.286 V10 (%)24.22 ± 9.0718.01 ± 9.001.7990.084 V20 (%)13.94 ± 6.379.18 ± 4.762.1680.039 V30 (%)7.34 ± 5.074.46 ± 2.421.8130.081 V40 (%)3.33 ± 3.491.69 ± 1.351.5390.136 MLD (Gy)7.80 ± 2.925.96 ± 2.291.8030.083Target areas Dose(Gy)62 ± 1469 ± 201.0980.2823 Volume(cm3)280(142–431)108(61–277)1.1860.2463 Comparison of dosimetric parameters between infected and non-infected groups in 36 lung cancer patients undergoing radiotherapy These findings suggest that current DVH parameters may need reevaluation in the context of immunotherapy. Additionally, the high incidence of pulmonary infections (58.3%, 21/36) underscores the importance of investigating mechanisms and predictive biomarkers associated with infection risk following combined radiotherapy and ICIs. It is notable that the V20 value in the infection group was significantly higher than that in the non-infection group (p = 0.0395). We speculate that the increase in V20 may increase the damage to the pulmonary mucosal barrier and create conditions for subsequent pathogen infections [17, 18]. Comparison of clinical characteristics between patients with and without pulmonary infections The cohort of 107 patients had a mean age of 63 years, with 89 (89/107, 83.2%) males and 86 (86/107, 80.4%) diagnosed with non-small cell lung cancer (NSCLC). PD-L1 expression ≥ 1% was observed in 26 patients (26/107, 24.3%), and the median number of ICIs treatment cycles was 4 (Q1, Q3: 2–6). Comparative analysis between the infected (n = 44) and non-infected (n = 63) groups revealed no significant differences in age, gender, BMI, KPS score, smoking history, diabetes status, tumor stage, histologic type, neutrophil-to-lymphocyte ratio(NLR), ICIs treatment regimen, GCsuse (≥ 3 weeks prior to infection), or radiotherapy dose/volume parameters (excluding V20) (all p > 0.05). Although this study found that the proportion of patients using glucocorticoids was higher in the infected group compared to the uninfected group (11.4% vs. 1.6%, p = 0.0794), the difference was not statistically significant, likely due to the limited sample size. Notably, patients receiving thoracic radiotherapy demonstrated significantly higher infection rates (47.7% vs. 23.8%, p = 0.0129), as did those with pre-existing ISIPA (27.3% vs. 9.5%, p = 0.0196) (see Table 3 ). These findings identify thoracic radiotherapy and pre-existing ISIPA were significantly associated with pulmonary infection following ICIs therapy. Table 3Baseline characteristics of individuals in the pulmonary infection group and the non-infection group (n = 107)CharacteristicsPI(n = 44)No PI(n = 63)All(n = 107)PMedian age, years65.02 ± 8.2761.95 ± 8.94763.21 ± 8.7670.0745Sex(%)0.6015M38(86.4)51(89.0)89(83.2)F6(13.6)12(19.0)18(16.8)KPS at baseline (median, Q1,Q3)90(90–90)90(90–90)90(90–90)0.2451BMI(kg/m2)23.32 ± 3.9023.06 ± 3.24 23.17±3.510.7045Tobacco Status (%)0.3261Never27(61.4)32(50.8)59(55.1)Current/Former17(38.6)31(49.2)48(44.9)T2DM(%)7(15.9)10(15.9)17(15.9)>0.9999HTN(%)16(36.4)18(28.6)34(31.8)>0.9999Histology (%)0.2005NSCLC38(86.4)48(76.2)86(80.4)SCLC5(11.4)14(22.2)19(17.8)Other1(2.3)1(1.6)2(1.9)TNM stage(%)0.5112I + II0(0)2(3.2)2(1.9)III + IV44(100)61(96.8)105(98.1)aLung disease at baseline(total,%)29(65.9)30(47.6)59(55.1)0.0765PPSH4(9.1)11(17.5)15(14.0)0.2675Prior ISIPA12(27.3)6(9.5)18(16.8)0.0196Prior COPD/PB/OE/CB/BA16(36.4)18(28.6)34(31.8)0.4075PTB(FPT/APT/LTBI)11(25.0)7(11.1)18(16.8)0.0701PD-L1 expression status (%)0.1699≥ 1%14(31.8)12(19.0)26(24.3)<1%/unknow30(68.2)51(81)81(75.7)ICIs usecycles (median,Q1,Q3)4(3–6)3(2–6)4(2–6)0.3539TRT(%)21(47.7)15(23.8)36(33.6)0.0129*bGCs use(%)5(11.4)1(1.6)6(5.6)0.0794NLR4.54 ± 13.384.16 ± 0.404.32 ± 0.300.5391hs-CRP(mg/L)65.91 ± 13.3837.90 ± 10.9655.02 ± 9.400.1489aLung disease at baseline(total,%) Some patients may have more than one lung disease at baseline bGCsuse:The use of Glucocorticoids (GCs) before lung infectionat a daily dose of ≥ 5 mg prednisone equivalent for a duration of 3 weeks or more. Baseline characteristics of individuals in the pulmonary infection group and the non-infection group (n = 107) aLung disease at baseline(total,%) Some patients may have more than one lung disease at baseline bGCsuse:The use of Glucocorticoids (GCs) before lung infectionat a daily dose of ≥ 5 mg prednisone equivalent for a duration of 3 weeks or more. Univariate and multivariate analyses of risk factors for pulmonary infections following ICIs therapy Univariate analysis identified three significant risk factors for post-ICI pulmonary infections: age ≥ 65 years (OR = 2.452, p = 0.0303), pre-existing ISIPA(OR = 3.563, p = 0.0196) and history of thoracic radiotherapy (OR = 2.922, p = 0.0129). Multivariate logistic regression analysis, incorporating all variables with p < 0.1 in univariate analysis (including pre-ICI PTB status and GCs use, Table 5), confirmed four independent risk factors: age ≥ 65 years (adjusted OR = 3.705, p = 0.007), pre-existing ISIPA (adjusted OR = 7.459, p = 0.001), TRT (adjusted OR = 5.141, p = 0.002), and pre-ICI PTB status(OR = 4.676,p = 0.015) (Table 4). These results demonstrate that both patient-specific factors (age and underlying lung conditions) and treatment-related factors (thoracic radiotherapy) significantly influence infection risk following ICIs treatment. Table 4Univariate and multivariate analysis of risk factors for pulmonary infections in lung cancer patients on ICIsRisk factorUnivariate analysisMultivariate analysisOR(95%CI)P-valueOR(95%CI)P-valueAge ≥ 65 years2.452(1.110–5.216)0.03033.705(1.2424–9.639)0.007ISIPA3.563(1.171–10.57)0.01967.459(2.250–24.734.250.734)0.001TRT2.922(1.225–6.809)0.01295.141(1.842–14.3494.842.3494)0.002a PTB(FPT/APT/LTBI)2.667(0.965–6.888)0.07014.676(1.343–16.276)0.015bGCS use7.949 (0.999–94.91)0.07948.206(0.847–79.457)0.069a PTB(FPT/APT/LTBI): pulmonary tuberculosis (Fibrotic Pulmonary Tuberculosis/Active Pulmonary Tuberculosis/Latent Tuberculosis infection status)b GCS use: The use of glucocorticoids ≥ 20 mg/day for ≥ 3 weeks before pneumonia onset Univariate and multivariate analysis of risk factors for pulmonary infections in lung cancer patients on ICIs a PTB(FPT/APT/LTBI): pulmonary tuberculosis (Fibrotic Pulmonary Tuberculosis/Active Pulmonary Tuberculosis/Latent Tuberculosis infection status) b GCS use: The use of glucocorticoids ≥ 20 mg/day for ≥ 3 weeks before pneumonia onset Discussion This study provides a comprehensive analysis of pulmonary infections following ICIs therapy in lung cancer patients. Our findings reveal several important clinical observations that warrant careful consideration in the management of patients receiving ICIs. The observed pulmonary infection rate of 41.1% in our cohort exceeds rates reported in previous studies (5%−19.2%) [12, 19], though remains lower than the 54.4% reported by Matthew Z Guo et al. [20]. This variation may be attributed to several factors: first, our population included a high proportion of patients with pre-existing pulmonary comorbidities (55.1%,59/107) and thoracic radiotherapy exposure (33.6%, 36/107); second, our study captured all infections occurring during and after ICIs treatment until study termination, rather than limiting to a fixed post-treatment window [21]. Notably, 56.8% of infections in our study had microbiological confirmation - substantially higher than the 8–50% reported elsewhere [19, 20]- likely reflecting our specialized respiratory hospital’s extensive use of advanced diagnostic techniques including next-generation sequencing and multiplex PCR of bronchoalveolar lavage fluid.Additionally, the occurrence of pulmonary infection with extrapulmonary infection, or isolated extrapulmonary infection, could reflect either systemic pathogen dissemination or altered immune function. Herpes virus infections in particular may suggest immune compromise.Immune status evaluation is recommended in such cases.The pathogen distribution pattern revealed several clinically relevant findings. Bacterial pathogens predominated, followed by fungal, viral, and mycobacterial organisms, consistent with prior reports [12]. However, the high frequency of polymicrobial infections (76.0%,19/25), particularly the common bacterial-fungal-viral combination, underscores the importance of broad-spectrum empirical coverage in these patient.The notable prevalence of Pneumocystis jirovecii (n = 7) among fungal infections underscores the importance of considering prophylactic trimethoprim-sulfamethoxazole for high-risk patients who are undergoing steroid treatment [22, 23]. Our unique findings regarding PTB are particularly noteworthy: among 16.8% (18/107)of patients with TB history, 61.1% (11/18)developed pulmonary infections post-ICI, including TB reactivation in 3 cases and new TB diagnoses in 2cases. In 2016, Kohei Fujita reported a case of advanced non-small cell lung cancer (NSCLC) in a patient with no prior history of tuberculosis who rapidly developed the disease during nivolumab treatment. This observation suggests that immune dysfunction following ICI therapy may contribute to the onset of tuberculosis [24]. In our study, the incidence of active pulmonary tuberculosis following ICI treatment was found to be 4.67% (5/107), which is significantly higher than the 1.7% reported in the literature [25]. The elevated incidence may be attributed to the high prevalence of tuberculosis in the region and factors related to specialized healthcare facilities. These data strongly suggest that in TB-endemic areas: (1) pre-ICI TB screening (IGRA/T-Spot) is essential [26]; (2) prophylactic anti-TB therapy should be considered for patients with LTBI; and (3) during treatment with immune checkpoint inhibitors, monitor regularly for active tuberculosis and initiate anti-tuberculosis treatment promptly if detected [27, 28].At present, the exact mechanism of tuberculosis reactivation following ICIs therapy remains elusive. Morelli, T. et al. also proposed that immune dysregulation might contribute to the pathogenesis, highlighting the need for further mechanistic studies [29]. The temporal pattern of infection onset (median 4 months, predominantly within 6 months but extending beyond 12 months), the severity distribution (41.1% overall, including 3.7% grade 2, 31.8% grade 3, 3.7% grade 4, and 1.9% grade 5), and the resulting permanent discontinuation of ICIs in 63.6%(28/44)of infected patients underscore the urgent need for vigilant monitoring, especially during the first 6 months, to prevent life-threatening pulmonary infection complications. Our multivariate analysis identified four independent risk factors: age ≥ 65 years (OR = 3.705), pre-existing ISIPA (OR = 7.459), Thoracic radiotherapy(OR = 5.141), and pre-existing PTB status(OR=4.676). The 58.3% infection rate in irradiated patients - despite dose-volume parameters being well below conventional thresholds - and the significantly higher V20 in infected patients (13.9% vs. 9.2%) suggest that ICIs may modulate pulmonary radiosensitivity through enhanced inflammatory responses [30]. We speculate that the inflammatory injury response in the lungs after chest radiotherapy is further amplified under the influence of ICIs, thereby creating conditions for pulmonary infection. Therefore, although DVH cannot directly predict pulmonary infection, it is meaningful to minimize the volume dose of both lungs as much as possible in the era of immunotherapy. Further research on models to predict the risk of pulmonary infection after ICIs combined with chest radiotherapy is necessary [31, 32]. This study has several limitations: First, the single-center retrospective design and relatively small sample size (n = 107) may introduce selection bias. The study population was predominantly male (83.2%, 89/107) and primarily consisted of patients with non-small cell lung cancer (80.4%, 86/107), with nearly all (98.1%, 105/107) presenting with stage III-IV disease. Furthermore, 55.1% (59/107) of participants had pre-existing pulmonary conditions, which may limit the generalizability of the findings to broader patient populations. With regard to treatment characteristics, 97.2% (104/107) of patients received PD-1 inhibitors, and 90.7% (97/107) underwent combination therapies that may independently influence the risk of infection. Notably, 4.67% (5/107) of cases had confirmed COVID-19 infection, which may have contributed to secondary pulmonary infections through immune modulation [33]. Importantly, 43.2% (19/44) of pulmonary infections were diagnosed based on clinical criteria without microbiological confirmation, and variations in follow-up duration may affect the accuracy of infection incidence estimates. The absence of a control group restricts the capacity for direct comparisons, and the outcomes may have been affected by confounding variables such as radiotherapy, chemotherapy, and immunosuppressants [34, 35]. These factors should be considered when interpreting the results. Conclusions In conclusion, our study demonstrates a high incidence (41.1%) of pulmonary infections in lung cancer patients treated with immune checkpoint inhibitors (ICIs), particularly among those with pre-existing lung disease, prior thoracic radiotherapy, or a history of tuberculosis (TB). Polymicrobial infections were common, emphasizing the need for broad-spectrum antimicrobial coverage in high-risk cases. Notably, TB reactivation occurred in 4.67% of patients, supporting the importance of pre-ICI TB screening and prophylactic therapy in endemic regions. Independent risk factors included age ≥ 65, pre-existing ISIPA, thoracic radiotherapy, and prior PTB, identifying subgroups requiring close monitoring. The potential interaction between ICIs and radiotherapy in increasing pulmonary toxicity warrants further investigation to optimize treatment strategies. However, the study’s retrospective design and single-center cohort limit generalizability. Future prospective studies are needed to validate these findings and develop predictive models for infection risk. Supplementary Information Supplementary material 1. Supplementary material 2. Supplementary material 3. Supplementary material 4. Supplementary material 5. Supplementary material 6. Supplementary material 7. Acknowledgements This work was supported by the Key Project of Medical Research of Xi’an Science and Technology Bureau:2024JH-YXZD-0069. Abbreviations Immune checkpoint inhibitors Programmed cell death protein 1/Programmed Cell Death-Ligand 1 Common Terminology Criteria for Adverse Events Pulmonarytuberculosis Thoracicradiotherapy Oddsratio lmaging-SuggestedInterstitialPulmonaryAbnormality immune-related adverse events Immune checkpoint inhibitor-associated pneumonitis Non-small cell lung cancer ) Chronic Obstructive Pulmonary Disease Radiation pneumonitis Body mass index Karnofsky Performance Status Fibrotic Pulmonary Tuberculosis Active Pulmonary Tuberculosis Latent tuberculosis infection Glucocorticoids Bronchoalveolar lavage fluid Targeted Next - Generation Sequencing for Respiratory Pathogens Tuberculin Skin Test T-cell Enzyme-Linked Immunospot Assay for Tuberculosis Tuberculosis Polymerase Chain Reaction Tuberculosis Deoxyribonucleic Acid Tuberculosis Ribonucleic Acid Xpert® Mycobacterium tuberculosis/Rifampin Equivalent dose of 2 Gy National Comprehensive Cancer Network Mean lung dose Dose-volumehistogram Pulmonary infection Neutrophil-to-lymphocyte ratio Male Female Type 2 Diabetes mellitus Hypertension Small cell lung cancer Past pulmonary surgery history Pulmonarybullae Obstructive emphysema Chronic bronchitis Bronchialasthma hypersensitive C-reactive protein Authors’ contributions HY, JL and YZ conceptualized the article.YH and XZ collect clinical data.SZ analyzed the data. HY and SZ wrote the initial draft. JL and YZ reviewed this article. The authors read and approved the finalmanuscript. Funding Key Project of Medical Research of Xi’an Science and Technology Bureau: 2024JH-YXZD-0069. Data availability All the data generated and analyzed during this study are included in this published article. Declarations Ethics approval and consent to participate This study was approved by the Institutional Review Board of Northwest University Affiliated Chest Hospital (Approval No. R2024-007-01),and informed consent forms were obtained from all patients prior to their participation in this study. All methods were carried out in accordance with relevant guidelines and regulations. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Yanjun Zhao, Email: 877018609@qq.com. Shanshan Zhang, Email: shanshanzhang0715@163.com. References Associated Data Supplementary Materials Supplementary material 1. Supplementary material 2. Supplementary material 3. Supplementary material 4. Supplementary material 5. Supplementary material 6. Supplementary material 7. Data Availability Statement All the data generated and analyzed during this study are included in this published article.